Board member Christine Riordan resigns from RE/MAX Holdings (RMAX) board

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

RE/MAX Holdings, Inc. reported a board change. On February 10, 2026, Dr. Christine Riordan informed the Board of Directors of her resignation, effective the same day. The company disclosed this change under the item covering departures of directors and certain officers.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Understanding 8-K Material Events →

02/11/2026 - 05:27 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 10, 2026

RE/MAX Holdings, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-36101

80-0937145

(State or other jurisdiction of

incorporation or organization)

(Commission

File Number)

(IRS Employer

Identification No.)

5075 South Syracuse Street

Denver, Colorado 80237

(Address of principal executive offices, including Zip code)

(303) 770-5531

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

	¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

	¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

	¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

	¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of Each Exchange on Which Registered
Class A Common Stock $0.0001 par value per share		RMAX		New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On February 10, 2026, Dr. Christine Riordan informed the Board of Directors (the “Board”) of RE/MAX Holdings, Inc. of her resignation from the Board, effective February 10, 2026.

This disclosure is made pursuant to Item 5.02(b) of Form 8-K.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	RE/MAX HOLDINGS, INC.

Date: February 11, 2026	By:	/s/ Susie Winders
		Susie Winders
		Executive Vice President and General Counsel

Source: View Original Filing on SEC EDGAR

FAQ

What board change did RE/MAX Holdings (RMAX) disclose in this 8-K?

RE/MAX Holdings disclosed the resignation of Dr. Christine Riordan from its Board of Directors. She informed the board of her decision on February 10, 2026, and the resignation was effective the same day, reflecting an immediate change in board composition.

When did Dr. Christine Riordan resign from the RE/MAX Holdings (RMAX) board?

Dr. Christine Riordan resigned from the RE/MAX Holdings board on February 10, 2026. She notified the Board of Directors and her resignation became effective that same day, resulting in an immediate departure from her director role.

Under which reporting item did RE/MAX Holdings (RMAX) disclose the director resignation?

The resignation was disclosed under Item 5.02, covering departures of directors or certain officers. This item is used to inform investors of significant changes in leadership, including board-level changes like Dr. Riordan’s departure.

Who signed the RE/MAX Holdings (RMAX) 8-K reporting the director resignation?

The report was signed by Susie Winders, Executive Vice President and General Counsel. Her signature indicates that the company formally authorized and validated the disclosure of Dr. Christine Riordan’s resignation from the Board of Directors.

What class of stock does RE/MAX Holdings (RMAX) list on the NYSE?

RE/MAX Holdings lists its Class A Common Stock on the New York Stock Exchange under the symbol RMAX. The shares have a par value of $0.0001 per share, as stated in the securities registration section.

Filing Exhibits & Attachments

3 documents